The article suggests the efficacy of a triple combination therapy consisting of ribavirin (RBV) in hepatitis C virus (HCV) treatment outcomes and anemia management. Several adverse effects of anemia on patient outcomes are cited including compromised quality of life, work productivity, and medication adherence. The importance of RBV dose reduction in anemia management is also elaborated.